{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:22:13Z","timestamp":1768036933078,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004061","name":"Oesterreichische Nationalbank","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.atherosclerosis.2020.02.011","type":"journal-article","created":{"date-parts":[[2020,2,16]],"date-time":"2020-02-16T04:07:15Z","timestamp":1581826035000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis"],"prefix":"10.1016","volume":"298","author":[{"given":"Oliver","family":"K\u00f6nigsbr\u00fcgge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Schmaldienst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Auinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Klauser-Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Tabernig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Kletzmayr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Enzenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Eigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Hecking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta M.","family":"Siller-Matula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib1","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice the sixth joint task force of the European society of cardiology","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0735-1097(02)02663-3","article-title":"Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community","volume":"41","author":"Manjunath","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib4","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF guideline AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular Disease\u00a0: 2011 update","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2020.02.011_bib5","first-page":"596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease","volume":"140","author":"Arnett","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/hdi.12571","article-title":"Antithrombotic therapy in end-stage renal disease","volume":"21","author":"Chunduri","year":"2017","journal-title":"Hemodial. Int."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0002-9343(03)00436-4","article-title":"Early and late effects of low-dose aspirin on renal function in elderly patients","volume":"115","author":"Segal","year":"2003","journal-title":"Amercian J Med"},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169400","article-title":"Prevalence of atrial fibrillation and antithrombotic therapy in hemodialysis patients: cross-sectional results of the Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on HemoDIalysis (VIVALDI)","volume":"12","author":"K\u00f6nigsbr\u00fcgge","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.thromres.2017.08.011","article-title":"Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: cross-sectional results of the Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemoDIalysis (VIVALDI","volume":"158","author":"K\u00f6nigsbr\u00fcgge","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib10","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib11","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.ajkd.2007.07.007","article-title":"Aspirin prescription and outcomes in hemodialysis Patients\u00a0: the dialysis outcomes and practice patterns study (DOPPS)","volume":"50","author":"Ethier","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10557-018-6802-1","article-title":"Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease Patients\u00a0: a multicenter randomized clinical trial ( AASER study )","volume":"32","author":"Goicoechea","year":"2018","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10557-019-06882-0","article-title":"Efficacy of antiplatelet agent usage for primary and secondary prevention in dialysis Patients\u00a0: a nationwide data survey and propensity analysis","volume":"33","author":"Chen","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2215\/CJN.04430416","article-title":"Article dual antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis","volume":"12","author":"Chen","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12928-016-0447-4","article-title":"Impact of stent type and prolonged dual antiplatelet therapy on long-term clinical outcomes in hemodialysis patients with coronary artery disease","volume":"33","author":"Asami","year":"2018","journal-title":"Cardiovasc Interv Ther"},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib16","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2009.06.049","article-title":"A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure","volume":"104","author":"Park","year":"2009","journal-title":"Amercian J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib17","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1182\/blood.V11.12.1073.1073","article-title":"Bleeding tendency in uremia","volume":"11","author":"Lewis","year":"1956","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1525-139X.2006.00179.x","article-title":"Platelet dysfunction and end-stage renal disease","volume":"19","author":"Kaw","year":"2006","journal-title":"Semin. Dial."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib19","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/j.1538-7836.2011.04531.x","article-title":"Antiplatelet effects of prasugrel vs . double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity","volume":"9","author":"Alexopoulos","year":"2011","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib20","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.jacc.2019.02.048","article-title":"Rivaroxaban plus aspirin in patients with vascular disease and renal dysfunction: from the COMPASS trial","volume":"73","author":"Fox","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib21","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jcin.2019.05.050","article-title":"Renal function and outcomes with dabigatran dual antithrombotic therapy in atrial fibrillation patients after PCI","volume":"12","author":"Hohnloser","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1681\/ASN.2017020201","article-title":"Should statins Be banned from Dialysis\u00a0?","volume":"28","author":"De Vriese","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2020.02.011_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11239-018-1644-z","article-title":"Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study","volume":"45","author":"Gurbel","year":"2018","journal-title":"J. Thromb. Thrombolysis"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020300915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020300915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:41:31Z","timestamp":1758156091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915020300915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":23,"alternative-id":["S0021915020300915"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.02.011","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}